MX2020001164A - Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. - Google Patents

Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.

Info

Publication number
MX2020001164A
MX2020001164A MX2020001164A MX2020001164A MX2020001164A MX 2020001164 A MX2020001164 A MX 2020001164A MX 2020001164 A MX2020001164 A MX 2020001164A MX 2020001164 A MX2020001164 A MX 2020001164A MX 2020001164 A MX2020001164 A MX 2020001164A
Authority
MX
Mexico
Prior art keywords
treatment
orogastrointestinal
composition
mucositis
prevention
Prior art date
Application number
MX2020001164A
Other languages
English (en)
Inventor
Vilaboa Deborah Rodriguez
Original Assignee
Mucosa Innovations S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucosa Innovations S L filed Critical Mucosa Innovations S L
Publication of MX2020001164A publication Critical patent/MX2020001164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por tratamientos oncológicos. También se refiere al uso de dicha composición para preparar un medicamento para la prevención y/o el tratamiento de dicha mucositis orogastrointestinal. Además, se refiere a un método de prevención y/o tratamiento de dicha mucositis orogastrointestinal en el que dicha composición se administra a un sujeto en necesidad del mismo.
MX2020001164A 2017-07-31 2018-07-30 Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. MX2020001164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382520 2017-07-31
PCT/EP2018/070594 WO2019025366A1 (en) 2017-07-31 2018-07-30 COMPOSITION FOR USE IN THE PREVENTION AND / OR TREATMENT OF ORAL AND GASTROINTESTINAL MUCITIS INDUCED BY ONCOLOGY TREATMENT

Publications (1)

Publication Number Publication Date
MX2020001164A true MX2020001164A (es) 2020-08-20

Family

ID=59581820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001164A MX2020001164A (es) 2017-07-31 2018-07-30 Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.

Country Status (14)

Country Link
US (2) US11160778B2 (es)
EP (1) EP3661490B1 (es)
JP (1) JP7096332B2 (es)
CN (1) CN111163762B (es)
AR (1) AR112291A1 (es)
AU (1) AU2018310609B2 (es)
BR (1) BR112020002138A2 (es)
DK (1) DK3661490T3 (es)
ES (1) ES2898258T3 (es)
MX (1) MX2020001164A (es)
PL (1) PL3661490T3 (es)
PT (1) PT3661490T (es)
RU (1) RU2762754C2 (es)
WO (1) WO2019025366A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661490B1 (en) 2017-07-31 2021-09-01 Mucosa Innovations, S.L. Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis
EP3706758B1 (en) * 2017-11-08 2022-06-29 Société des Produits Nestlé S.A. Bioconversion of oleuropein
IT202000002146A1 (it) * 2020-02-04 2021-08-04 Foodar Advanced Res S R L Composizione per la prevenzione ed il trattamento di mucositi
AU2021225354B2 (en) 2020-02-28 2024-06-20 Mucosa Innovations, S.L. Composition for the prevention and treatment of dysbiosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
ES2304103B1 (es) * 2007-02-22 2009-08-07 Biocosmetics S.L. Composicion para tratamiento de la xerostomia o boca seca.
ITMI20080038A1 (it) * 2008-01-11 2009-07-12 Indena Spa Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva
CN101973854B (zh) * 2010-11-09 2014-01-01 中国林业科学研究院林产化学工业研究所 一种从油橄榄叶中高效富集羟基酪醇的方法
CN102526095A (zh) * 2012-02-14 2012-07-04 济南康众医药科技开发有限公司 一种治疗卡他症的药物组合物
JP6779871B2 (ja) 2015-06-22 2020-11-04 株式会社明治 がん患者のための口腔ケア用組成物
EP3661490B1 (en) 2017-07-31 2021-09-01 Mucosa Innovations, S.L. Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis

Also Published As

Publication number Publication date
DK3661490T3 (da) 2021-11-22
PL3661490T3 (pl) 2022-01-24
US20220031647A1 (en) 2022-02-03
CN111163762A (zh) 2020-05-15
US11160778B2 (en) 2021-11-02
JP7096332B2 (ja) 2022-07-05
EP3661490A1 (en) 2020-06-10
EP3661490B1 (en) 2021-09-01
US11654127B2 (en) 2023-05-23
RU2762754C2 (ru) 2021-12-22
RU2020105039A3 (es) 2021-09-02
WO2019025366A1 (en) 2019-02-07
AR112291A1 (es) 2019-10-09
RU2020105039A (ru) 2021-09-02
ES2898258T3 (es) 2022-03-04
AU2018310609B2 (en) 2024-03-21
BR112020002138A2 (pt) 2020-08-04
AU2018310609A1 (en) 2020-02-20
JP2020529475A (ja) 2020-10-08
CN111163762B (zh) 2023-07-18
US20200170988A1 (en) 2020-06-04
PT3661490T (pt) 2021-11-05

Similar Documents

Publication Publication Date Title
MX2019009443A (es) Metodos para tratar la influenza.
PH12018500642A1 (en) Anti-garp antibody
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
PH12019501706A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2019012884A (es) Terapia de combinacion.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
BR112017013982A2 (pt) fármaco de combinação
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12016502322B1 (en) Compounds and methods for preventing or treating malaria
MX2021001228A (es) Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria.
MX2016008968A (es) Compuestos organicos.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
EA201992234A1 (ru) Средство для профилактики миопии, лечения миопии и/или предотвращения прогрессирования миопии, включающее тиотропий в качестве активного ингредиента
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.